A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Inclusion Criteria: * Voluntary participation in a clinical trial and signed informed consent. * Ages 18 to 75 years (inclusive of the boundaries), male or female. * Participants with advanced or unresectable HCC confirmed by pathological histology or diagnosed in accordance with the clinical criteria specified in the National Health Commission guidelines, with the following additional requirements: * Participants with HCC who have experienced progressive disease after prio systemic therapy; * Tumor tissue IHC testing for FGF19 was positive (confirmed by central laboratory); * Child-Pugh class A or class B (Child-Pugh score ≤7) ; * Barcelona Clinic Liver Cancer (BCLC) stage B or C * ECOG score 0 or 1 * Have at least one measurable lesion according to RECIST v1.1. * Life expectancy ≥ 12 weeks. * Adequate organ and bone marrow function. * Participants with HCV infection, whose HCV-RNA levels are above the lower limit of detection at the study site, are eligible if antiviral therapy is initiated prior to the first dose administration. * Participants with hepatitis B virus (HBV) infection must have HBV DNA \< 104 cps/mL or 2,000 IU/mL. * Participants (including partners of the male participants) are willing to use effective contraception from the screening period until 6 months after the last investigational product administration. Exclusion Criteria: * Participated in another clinical trial of investigational drugs or investigational medical devices within 28 days pr…